NeuroKet 2.0: Ketamine Effects on Brain Function in Difficult-to-Treat Depression

De-identified clinical, behavioral, neuroimaging, and passive sensing data from an interventional randomized controlled trial examining the neural and symptomatic effects of a single subcutaneous ketamine dose in adults with difficult-to-treat depression. The dataset includes ultra-high field 7 Tesla functional MRI, clinician-rated and self-reported symptom measures, and objective behavioral data from actigraphy and mobile sensing. It was created by MACH HeSANDA and is expected to be available for request following publication of the primary outcome paper.

Use Cases

• Analyzing changes in habenula activity and connectivity based on 7 Tesla fMRI scans before and after ketamine administration.
• Correlating clinician-rated depressive symptom scores with objective behavioral measures from actigraphy and passive mobile sensing.
• Investigating the relationship between ketamine intervention and self-reported measures of anxiety, anhedonia, motivation, and quality of life.
• Comparing neural and symptomatic responses between ketamine, saline placebo, and healthy control groups.

Strengths

• Data includes ultra-high field 7 Tesla functional MRI, which provides high-resolution neuroimaging.
• The study design is a randomized controlled trial with a saline placebo group and a healthy control group.
• Multimodal data collection combines clinical, behavioral, neuroimaging, and passive sensing measures.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is from an ongoing study, with the last data collection expected on 20/12/2027.

Provenance

Source

MACH HeSANDA

Collection Method

Collected from an interventional randomized controlled study.

Freshness

Last updated 2026-04-28 23:37:42; freshness should be verified.